QUIETILINE
MOBEN
Identification
- Active ingredient (INN)
- BROMAZEPAM
- Internal code
- 16 B 098
- Country of Origin
- Algeria
- Pharmaceutical form
- Quadrisected Tablet
- Prescription List
- Highly Regulated (List I)
- Packaging
- B/30
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
One of the benzodiazepines that is used in the treatment of anxiety disorders.
It is a Schedule Intravenous drug in the U.S. and Canada and under the Convention on Psychotropic Substances.
It is a intermediate-acting benzodiazepine.
Indications
For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol.
- and opiate-withdrawal.
Pharmacodynamics
Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties.
It does not possess any antidepressant qualities.
Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence.
According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.
Mechanism of Action
Receptor Positive allosteric modulator
GABA(A) Receptor Benzodiazepine Binding Site Ligand.
Absorption
Bioavailability is 84% following oral administration.
The time to peak plasma level is 1-4 hours.
Bromazepam is generally well absorbed after oral administration.
Metabolism
Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes).
One of the main metabolites is 3-hydroxybromazepam.
It is pharmacologically active and the half life is similar to that of the parent compound.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.